News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xcyte Therapies, Inc. And Invitrogen Corporation (IVGN) Announce Signing Of Asset Purchase Agreement


12/15/2005 11:25:49 AM

SEATTLE & CARLSBAD, Calif.--(BUSINESS WIRE)--Dec. 15, 2005--Xcyte Therapies, Inc. (Xcyte) (Nasdaq:XCYT) (Nasdaq:XCYTP) and Invitrogen Corporation (Nasdaq:IVGN) today announced they have entered into a definitive agreement for Invitrogen to acquire Xcyte's T cell expansion technology, known as the "Xcellerate Process." The acquired assets will include intellectual property, the clinical data generated by Xcyte in the course of six clinical trials of its lead product, Xcellerated T Cells, as well as raw materials and equipment.

Read at BioSpace.com
Read at AP


comments powered by Disqus
BioSpace.com
AP
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES